CorMe
CorMedix (CRMD) got here out with a quarterly lack of $0.21 per share versus the Zacks Consensus Estimate of a lack of $0.24. This compares to earnings of $0.10 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of 12.50%. 1 / 4 in the past, it was anticipated that this pharmaceutical and medical gadget firm would put up a lack of $0.25 per share when it truly produced a lack of $0.22, delivering a shock of 12%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates 3 times.
CorMedix, which belongs to the Zacks Medical – Biomedical and Genetics business, posted revenues of $0.03 million for the quarter ended December 2019, lacking the Zacks Consensus Estimate by 73.68%. This compares to year-ago revenues of $0.03 million. The corporate has topped consensus income estimates simply as soon as during the last 4 quarters.
The…